1
|
Shelly S, Soontrapa P, Madigan NN, Polzin MJ, Singh TD, Sista SRS, Paul P, Braksick SA, Liao B, Windebank AJ, Boon AJ, Litchy WJ, Milone M, Liewluck T. Compound Muscle Action Potential and Myosin-Loss Pathology in Patients With Critical Illness Myopathy: Correlation and Prognostication. Neurology 2024; 103:e209496. [PMID: 38870464 DOI: 10.1212/wnl.0000000000209496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Prolonged compound muscle action potential (CMAP) duration and preferential loss of myosin are considered the diagnostic hallmarks of critical illness myopathy (CIM); however, their correlation and prognostic values have not been studied. We aimed to investigate the correlation between CMAP duration and myosin loss and their effect on mortality by comparing between patients with CIM with and without myosin loss. METHODS We searched the Mayo Clinic Electromyography Laboratory databases (1986-2021) for patients diagnosed with CIM on the basis of prolonged distal CMAP durations (>15 msec in fibular motor nerve studies recording over the tibialis anterior or >8 msec in other motor nerves) and needle EMG findings compatible with myopathy. Electrodiagnostic studies were generally performed within 24 hours after weakness became noticeable. We included only patients who underwent muscle biopsy. Clinical, electrophysiologic, and myopathologic data were reviewed. We conducted myosin/actin ratio analysis when muscle tissue was available. We used the Fisher exact test for categorical data comparisons and the Mann-Whitney 2-tailed test for continuous data. We applied the Kaplan-Meier technique to analyze survival rates. RESULTS Twenty patients (13 female patients) were identified [median age at diagnosis of 62.5 years (range: 19-80 years)]. The median onset of weakness was 24 days (range: 1-128) from the first day of intensive care unit admission. Muscle biopsy showed myosin loss in 14 patients, 9 of whom had >50% of myofibers affected (high grade). Type 2 fiber atrophy was observed in 19 patients, 13 of whom also had myosin loss. Patients with myosin loss had higher frequency of steroid exposure (14 vs 3; p = 0.004); higher median number of necrotic fibers per low-power field (2.5 vs 1, p = 0.04); and longer median CMAP duration (msec) of fibular (13.4 vs 8.75, p = 0.02), tibial (10 vs 7.8, p = 0.01), and ulnar (11.1 vs 7.95, p = 0.002) nerves compared with those without. Only patients with high-grade myosin loss had reduced myosin/actin ratios (<1.7). Ten patients died during median follow-up of 3 months. The mortality rate was similar between patients with and without myosin loss. Patients with high-grade myosin loss had a lower overall survival rate than those with low-grade or no myosin loss, but this was not statistically significant (p = 0.05). DISCUSSION Myosin loss occurred in 70% of the patients with CIM with prolonged CMAP duration. Longer CMAP duration predicts myosin-loss pathology. The extent of myosin loss marginally correlates with the mortality rate. Our findings highlight the potential prognostic values of CMAP duration and myosin loss severity in predicting disease outcome.
Collapse
Affiliation(s)
- Shahar Shelly
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Pannathat Soontrapa
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Nicolas N Madigan
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Michael J Polzin
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Tarun D Singh
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Sri Raghav S Sista
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Pritikanta Paul
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Sherri A Braksick
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Bing Liao
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Anthony J Windebank
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Andrea J Boon
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - William J Litchy
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Margherita Milone
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| | - Teerin Liewluck
- From the Department of Neurology (S.S., P.S., N.N.M., M.J.P., S.A.B., A.J.W., A.J.B., W.J.L., M.M., T.L.), Mayo Clinic, Rochester, MN; Department of Neurology (S.S.), Rambam Medical Center, Haifa, Israel; Division of Neurology (P.S.), Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Neurology (T.D.S.), University of Michigan, Ann Arbor; Department of Neurology (S.R.S.S.), University of Texas Health Sciences at Houston; Department of Neurology (P.P.), University of California, San Francisco; Department of Neurology (B.L.), Houston Methodist Hospital, TX; and Department of Physical Medicine and Rehabilitation (A.J.B.), Mayo Clinic, Rochester, MN
| |
Collapse
|
4
|
Cacciani N, Skärlén Å, Wen Y, Zhang X, Addinsall AB, Llano-Diez M, Li M, Gransberg L, Hedström Y, Bellander BM, Nelson D, Bergquist J, Larsson L. A prospective clinical study on the mechanisms underlying critical illness myopathy-A time-course approach. J Cachexia Sarcopenia Muscle 2022; 13:2669-2682. [PMID: 36222215 PMCID: PMC9745499 DOI: 10.1002/jcsm.13104] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 08/23/2022] [Accepted: 09/12/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Critical illness myopathy (CIM) is a consequence of modern critical care resulting in general muscle wasting and paralyses of all limb and trunk muscles, resulting in prolonged weaning from the ventilator, intensive care unit (ICU) treatment and rehabilitation. CIM is associated with severe morbidity/mortality and significant negative socioeconomic consequences, which has become increasingly evident during the current COVID-19 pandemic, but underlying mechanisms remain elusive. METHODS Ten neuro-ICU patients exposed to long-term controlled mechanical ventilation were followed with repeated muscle biopsies, electrophysiology and plasma collection three times per week for up to 12 days. Single muscle fibre contractile recordings were conducted on the first and final biopsy, and a multiomics approach was taken to analyse gene and protein expression in muscle and plasma at all collection time points. RESULTS (i) A progressive preferential myosin loss, the hallmark of CIM, was observed in all neuro-ICU patients during the observation period (myosin:actin ratio decreased from 2.0 in the first to 0.9 in the final biopsy, P < 0.001). The myosin loss was coupled to a general transcriptional downregulation of myofibrillar proteins (P < 0.05; absolute fold change >2) and activation of protein degradation pathways (false discovery rate [FDR] <0.1), resulting in significant muscle fibre atrophy and loss in force generation capacity, which declined >65% during the 12 day observation period (muscle fibre cross-sectional area [CSA] and maximum single muscle fibre force normalized to CSA [specific force] declined 30% [P < 0.007] and 50% [P < 0.0001], respectively). (ii) Membrane excitability was not affected as indicated by the maintained compound muscle action potential amplitude upon supramaximal stimulation of upper and lower extremity motor nerves. (iii) Analyses of plasma revealed early activation of inflammatory and proinflammatory pathways (FDR < 0.1), as well as a redistribution of zinc ions from plasma. CONCLUSIONS The mechanical ventilation-induced lung injury with release of cytokines/chemokines and the complete mechanical silencing uniquely observed in immobilized ICU patients affecting skeletal muscle gene/protein expression are forwarded as the dominant factors triggering CIM.
Collapse
Affiliation(s)
- Nicola Cacciani
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Åsa Skärlén
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Ya Wen
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Xiang Zhang
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Alex B Addinsall
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Monica Llano-Diez
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Meishan Li
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Lennart Gransberg
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Yvette Hedström
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Bo-Michael Bellander
- Section of Neurosurgery, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - David Nelson
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.,Section of Intensive Care, Function Perioperative Medicine and Intensive Care (PMI), Karolinska University Hospital, Stockholm, Sweden
| | - Jonas Bergquist
- Analytical Chemistry and Neurochemistry, Department of Chemistry-Biomedical Centre, Uppsala University, Uppsala, Sweden.,The Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centre at Uppsala University, Uppsala, Sweden
| | - Lars Larsson
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.,The Viron Molecular Medicine Institute, Boston, MA, USA
| |
Collapse
|